Compare Diagnos Laboratorium Utama Tbk. (DGNS) vs UBC Medical Indonesia Tbk. (LABS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diagnos Laboratorium Utama Tbk. vs UBC Medical Indonesia Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp232 (market cap 316.25B, 41.7K 24h volume), while UBC Medical Indonesia Tbk. trades at Rp165 (market cap 635.95B, 843K 24h volume). The key difference: UBC Medical Indonesia Tbk. is far larger — about 2× Diagnos Laboratorium Utama Tbk.'s market cap, and UBC Medical Indonesia Tbk. is more actively traded (843K versus 41.7K). Which is the better fit depends on your goals.
| DGNS | LABS | |
|---|---|---|
Market Cap | 316.25B | 635.95B |
Volume | 41.7K | 843K |
Lot | 417 | 8.43K |
Turnover | 9.66M | 137.6M |
Average Price | 231.65 | 163.22 |
Value | 9.66M | 137.6M |
Indicative Equilibrium Price | 230 | 165 |
Indicative Equilibrium Volume | 2.4K | 246 |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diagnos Laboratorium Utama Tbk.
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →About UBC Medical Indonesia Tbk.
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →
